Molnar, Daniel http://orcid.org/0000-0002-6785-3812
La, Elizabeth M. http://orcid.org/0000-0001-5652-8961
Verelst, Frederik http://orcid.org/0000-0001-8399-743X
Poston, Sara http://orcid.org/0000-0003-4735-057X
Graham, Jonathan http://orcid.org/0000-0002-3227-5928
Van Bellinghen, Laure-Anne http://orcid.org/0000-0003-2641-6787
Curran, Desmond http://orcid.org/0000-0002-7423-0111
Funding for this research was provided by:
GlaxoSmithKline Biologicals
Article History
Received: 12 December 2023
Accepted: 7 February 2024
First Online: 20 March 2024
Declarations
:
: Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, and Desmond Curran are employees of GSK and hold shares in GSK. Jonathan Graham is an employee of RTI Health Solutions, which received consultancy fees from GSK to complete the work disclosed here and for other projects unrelated to the submitted work. Laure-Anne Van Bellinghen is an employee of CHESS in Health, which received funding from GSK to complete the work disclosed here and for additional projects unrelated to the present study.
: This analysis is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Ethical approval for the development of the model was not required.